Antibody-based cancer therapy

Over the past 25 years, antibody therapeutics have emerged as clinically and commercially successful pharmaceuticals, rapidly approaching 100 Food and Drug Administration approvals with combined annual global sales exceeding $100 billion. Nearly half of the marketed antibody therapeutics are used in oncology. These antibody-based cancer therapies can be broken down into three categories based on their different mechanisms of action, i.e., (i) natural properties, (ii) engagement of cytotoxic T cells, and (iii) delivery of cytotoxic payloads. Both natural and engineered properties of the antibody molecule are founded on its highly stable and modular architecture. In this review we provide an overview and outlook of the rapidly evolving landscape of antibody-based cancer therapy.

Automated summary

Over the past 25 years, antibody therapeutics have become successful pharmaceuticals, particularly in the field of oncology. These therapies work through natural properties, engagement of cytotoxic T cells, and delivery of cytotoxic payloads. The success of antibody-based cancer therapy is built on both natural and engineered properties of the antibody molecule.